- Processing Solutions
- White Papers
- Tech Portals
- Buyer's Guide
COPENHAGEN, Denmark — Pharmaceutical company H. Lundbeck A/S today announced that its partners Mochida Pharmaceutical Co., Ltd. and Mitsubishi Tanabe Pharma Corporation have launched Lexapro® 10mg (escitalopram) in Japan, according to a press release.
Lexapro® has been very well-received by patients and doctors for the treatment of depression in many countries, and is currently the most prescribed branded anti-depressant in the world, the release stated.
“It is a milestone in our global expansion strategy that Lexapro® is now available in Japan following a fast regulatory process,” said Lundbeck Senior Vice President Ole Chrintz, International Markets. “We are pleased that Lexapro® will now also contribute to improving quality of life for patients in Japan diagnosed with depression.”